Clinical trial · no report yet · Phase 3
PROUD-PV
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
- NCT01949805 ↗
- Completed
- AOP Orphan Pharmaceuticals AG
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 24 | |
| Podcasts | 12 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Polycythemia Vera
- Interventions
- Peg-P-IFN-alpha-2b (AOP2014); Hydroxyurea
- Arms
- Hydroxyurea · Active comparator
- Peg-P-IFN-alpha-2b (AOP2014) · Experimental
- Enrollment
- 257
- Primary outcomes
- Disease response rate
- Sponsor
- AOP Orphan Pharmaceuticals AG with PharmaEssentia (Co-Sponsor for USA)
- Start
- Sep 2013
- Primary completion
- Jul 2016
- Results posted
- No
- Registry record
- NCT01949805 · updated Nov 28, 2016
Publications
linked from the registry- Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0. PubMed 30287855